









Markets
/
Stocks
/
nasdaq-canf
/

Can Fite Biopharma Ltd

CANF

0.646USD

-0.001-0.08%

Close 09/17, 16:00（ET）Quotes delayed by 15 min

2.56BMarket Cap

LossP/E TTM



Can Fite Biopharma Ltd

0.646

-0.001-0.08%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company has shown average stock market performance, with mediocre fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

123 / 175

Overall Ranking

391 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.167

Target Price

+1625.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Growing

The company is in a growing phase, with the latest annual income totaling USD 674.00K.

Fairly Valued

The company’s latest PE is -178.59, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 155.14K shares, decreasing 82.10% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.49.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 5.51, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 155.00K, representing a year-over-year decrease of 21.32%, while its net profit experienced a year-over-year decrease of 45.28%.

Score

Industry at a Glance

Previous score

5.51

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.55

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -178.59, which is -13.49% below the recent high of -154.51 and -97.90% above the recent low of -353.43.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 123/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Can Fite Biopharma Ltd is 11.00, with a high of 18.00 and a low of 4.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.167

Target Price

+1625.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Can Fite Biopharma Ltd

CANF

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 2.45, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 0.67 and the support level at 0.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.15

Change

0.3

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.016

Neutral

RSI(14)

36.387

Neutral

STOCH(KDJ)(9,3,3)

26.834

Sell

ATR(14)

0.018

High Vlolatility

CCI(14)

-120.581

Sell

Williams %R

60.411

Sell

TRIX(12,20)

-0.431

Sell

StochRSI(14)

9.695

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.652

Sell

MA10

0.653

Sell

MA20

0.655

Sell

MA50

0.760

Sell

MA100

0.917

Sell

MA200

1.238

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Rhumbline Advisers Ltd. Partnership

38.27K

+42.37%

Abalone Asset Management Ltd.

23.81K

-40.48%

BNP Paribas Securities Corp. North America

22.59K

-10.32%

CAPTRUST Financial Advisors

10.63K

Morgan Stanley & Co. LLC

23.21K

-28.60%

MainStreet Advisors

3.00K

Wells Fargo Advisors

2.70K

+8.00%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.03, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.